Last reviewed · How we verify
NCT05967455
Homologous Re-infection With Dengue 1 or Dengue 3
Phase 1 trial testing Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC) in Dengue in 9 participants. Completed in 26 August 2024.
26 August 2024
Quick facts
| Lead sponsor | State University of New York - Upstate Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 9 |
| Start date | 30 October 2023 |
| Primary completion | 26 August 2024 |
| Estimated completion | 26 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC) — full drug profile →
- Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) — full drug profile →
Conditions studied
- Dengue — all drugs for Dengue →
Sponsor
State University of New York - Upstate Medical University
Who can join
Adults 18 to 55, any sex, with Dengue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Previous studies with one dengue infection in a controlled environment at Upstate generated data that has been important in understanding the clinical signs and symptoms and how a person's body reacts to dengue infection over time. This has helped investigators compare what is seen in the clinic to what is seen in areas where dengue is prevalent. The investigators want to collect similar information when a person gets the same dengue twice in a controlled environment with the hope that this will lead them to a better understanding of the disease. New participants * will receive one inoculation of dengue and then return to the clinic or be contacted by phone over 6 months; * will receive a second inoculation after 6 months and return to the clinic or be contacted by phone for three more months; * will collect saliva at home; * will allow the study team to collect blood and saliva at the clinic visits. Participants who have been in previous dengue inoculation studies at SUNY Upstate * will receive one inoculation of dengue and then return to the clinic or be contacted by phone over 6 months; * will collect saliva at home; * will allow the study team to collect blood and saliva at the clinic visits. All participants will be seen in the clinic every other day for the first three weeks after any inoculation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05967455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dengue
Currently open trials in the same condition.
- NCT07501793 — Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam · active not recruiting
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07007585 — Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection · recruiting
- NCT06894901 — Impact of IIT-SIT on Dengue Clusters · NA · recruiting
- NCT07158190 — Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda). · active not recruiting
Other State University of New York - Upstate Medical University trials
Trials by the same sponsor.
- NCT07220031 — Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay · not yet recruiting
- NCT04736953 — Sirolimus Treatment Of Patients With SLE · Phase 2 · not yet recruiting
- NCT06370442 — Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult · Phase 3 · not yet recruiting
- NCT06045650 — Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder · not yet recruiting
- NCT06112093 — Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05967455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York - Upstate Medical University
- Last refreshed: 13 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing